COL1A1 and pulmonary fibrosis: Our team recently reported the synthesis of novel N-(2-aminophenyl)-benzamide inhibitors of Class I HDACs, specifically HDAC1, 2 and 3, and compounds GK444 and GK718 (2 and 3, Figure 2, IC50 values in the range from 100 to 361 nΜ and 139 to 259 nM, respectively) were investigated in a mouse model of bleomycin-induced pulmonary fibrosis, showing efficacy on a preventative dosing schedule (30 mg/kg daily), with decreased Col1a1 gene expression, fibrotic masses, and collagen deposition [25].